Swedbank AB Has $327.02 Million Stock Holdings in Intuitive Surgical, Inc. $ISRG

Swedbank AB grew its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 38.4% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 731,221 shares of the medical equipment provider’s stock after acquiring an additional 202,807 shares during the period. Swedbank AB owned about 0.20% of Intuitive Surgical worth $327,024,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the business. Optas LLC lifted its holdings in Intuitive Surgical by 35.6% during the 3rd quarter. Optas LLC now owns 975 shares of the medical equipment provider’s stock worth $436,000 after buying an additional 256 shares during the period. DAVENPORT & Co LLC increased its stake in shares of Intuitive Surgical by 39.6% in the third quarter. DAVENPORT & Co LLC now owns 160,004 shares of the medical equipment provider’s stock valued at $71,236,000 after buying an additional 45,427 shares during the period. Meriwether Wealth & Planning LLC raised its position in shares of Intuitive Surgical by 5.2% during the third quarter. Meriwether Wealth & Planning LLC now owns 1,204 shares of the medical equipment provider’s stock worth $538,000 after acquiring an additional 59 shares during the last quarter. Welch Group LLC lifted its stake in shares of Intuitive Surgical by 9.8% in the third quarter. Welch Group LLC now owns 505 shares of the medical equipment provider’s stock worth $226,000 after acquiring an additional 45 shares during the period. Finally, True North Advisors LLC boosted its holdings in Intuitive Surgical by 7.0% in the third quarter. True North Advisors LLC now owns 2,338 shares of the medical equipment provider’s stock valued at $1,046,000 after acquiring an additional 152 shares during the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

Insider Activity at Intuitive Surgical

In other Intuitive Surgical news, CEO David J. Rosa sold 24,500 shares of the company’s stock in a transaction on Friday, October 24th. The shares were sold at an average price of $547.55, for a total transaction of $13,414,975.00. Following the transaction, the chief executive officer owned 234,256 shares in the company, valued at approximately $128,266,872.80. This represents a 9.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP Mark Brosius sold 4,500 shares of the firm’s stock in a transaction on Friday, December 12th. The shares were sold at an average price of $547.36, for a total transaction of $2,463,120.00. Following the completion of the transaction, the senior vice president directly owned 907 shares in the company, valued at $496,455.52. This trade represents a 83.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 114,007 shares of company stock valued at $63,533,844 over the last three months. 0.70% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. Daiwa Capital Markets upped their price objective on shares of Intuitive Surgical from $510.00 to $550.00 and gave the company an “outperform” rating in a research note on Friday, October 24th. Robert W. Baird set a $655.00 price target on shares of Intuitive Surgical in a research report on Wednesday, October 22nd. Piper Sandler increased their price target on Intuitive Surgical from $595.00 to $610.00 and gave the stock an “overweight” rating in a report on Wednesday, October 22nd. Zacks Research raised Intuitive Surgical from a “hold” rating to a “strong-buy” rating in a research note on Friday, October 24th. Finally, Sanford C. Bernstein restated an “outperform” rating and set a $685.00 target price on shares of Intuitive Surgical in a research report on Tuesday, October 21st. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Intuitive Surgical currently has a consensus rating of “Moderate Buy” and a consensus price target of $611.08.

Intuitive Surgical Price Performance

ISRG stock opened at $577.34 on Wednesday. The company’s 50-day moving average is $547.18 and its 200-day moving average is $505.91. The stock has a market capitalization of $206.96 billion, a PE ratio of 76.37, a price-to-earnings-growth ratio of 5.33 and a beta of 1.68. Intuitive Surgical, Inc. has a 1 year low of $425.00 and a 1 year high of $616.00.

Intuitive Surgical (NASDAQ:ISRG) last issued its earnings results on Tuesday, October 21st. The medical equipment provider reported $2.40 EPS for the quarter, beating analysts’ consensus estimates of $1.99 by $0.41. The business had revenue of $2.51 billion during the quarter, compared to analyst estimates of $2.41 billion. Intuitive Surgical had a return on equity of 15.08% and a net margin of 28.58%.The firm’s revenue was up 22.9% compared to the same quarter last year. During the same period in the previous year, the company posted $1.84 EPS. On average, analysts anticipate that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current fiscal year.

About Intuitive Surgical

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.